Survey Highlights Successes and Challenges for Early Adopters of Clinical NGS | GenomeWeb

This article was originally published July 29.

NEW YORK (GenomeWeb) — As interest in using clinical sequencing to personalize medicine begins to expand past the initial vanguard of early adopters, researchers from several institutions participating in a College of American Pathologists workgroup have attempted to tease out some of the decision-making behind the implementation of these pioneering programs in hopes of helping to guide the future spread of genomic medicine.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PLOS this week: cell-free DNA from tumors is shorter than DNA from healthy cells, type 2 diabetes-related loci, and more.

Genetic analysis confirms that blood found on leaves collected near Marche-les-Dames some 80 years ago belongs to King Albert I of Belgium.

Researchers in the US begin to seek participants for the 1 million-person precision medicine cohort, the New York Times reports.

A new report indicates that women are underrepresented among US patent holders.